Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Intrinsic Value
Vertex Pharmaceuticals, Inc. is a global biotechnology company. [ Read More ]
The intrinsic value of one
VRTX
stock under the Base Case scenario is
249.59
USD.
Compared to the current market price of 399.78 USD,
Vertex Pharmaceuticals Inc
is
Overvalued by 38%.
Vertex Pharmaceuticals Inc's market capitalization is 103B USD.
VRTX stock price is 399.78 USD.
VRTX stock (249.59 USD) is 38% less than its price (399.78 USD).
VRTX stock (247.08 USD) is 38% less than its price (399.78 USD). Open Relative Valuation
VRTX has upside potential of 19% compared to the average analyst price target.
Open Wall St Estimates
VRTX's Revenue has grown by 11% over the past 12 months.
VRTX's Revenue is forecast to grow at a rate of 10% per year over the next 3 years.
VRTX's ROIC (Return on Invested Capital) has decreased in the last 3 years from 53% to 44%.
VRTX's ROE (Return on Equity) for the past 12 months is positive and is equal to 23%.
VRTX's ROE (Return on Equity) has significantly decreased in the last 3 years from 36% to 23%.
VRTX's Revenue has been growing by 17% per year for the last 3 years.
VRTX's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 44%.
VRTX has positive Net Income for the last twelve months.
VRTX has very high three-year average ROE (Return on Equity): 27%. The company is very efficient at transforming stockholders' equity into net income.
VRTX has positive Operating Income for the last twelve months.
VRTX has positive Gross Profit for the last twelve months.
VRTX has positive Free Cash Flow for the last twelve months.
VRTX has very high three-year average ROIC (Return on Invested Capital): 47%. The company is very efficient at using invested capital to generate operating income.
VRTX's D/E (Debt to Equity) is very low and is equal to 0.02.
VRTX's short-term assets (14B USD) exceed its short-term liabilties (4B USD).
VRTX's long-term assets (23B USD) exceed its long-term liabilties (5B USD).
VRTX has negative Net Debt. This means that the company has more cash and short-term investments (12B USD) than debt (376m USD).
VRTX's Altman Z-Score is very high and is equal to 13.75.
VRTX earns more than enough operating income (4B USD) to safely cover interest payments on its debt (43m USD).
Valuation Backtest
Vertex Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
VRTX
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Vertex Pharmaceuticals Inc
Balance Sheet Decomposition
Vertex Pharmaceuticals Inc
| Current Assets | 14.1B |
| Cash & Short-Term Investments | 12.1B |
| Receivables | 1.6B |
| Other Current Assets | 513.3m |
| Non-Current Assets | 8.6B |
| Long-Term Investments | 2.6B |
| PP&E | 1.5B |
| Intangibles | 1.9B |
| Other Non-Current Assets | 2.6B |
| Current Liabilities | 3.5B |
| Accounts Payable | 3.4B |
| Accrued Liabilities | 2.7B |
| Other Current Liabilities | -2.5B |
| Non-Current Liabilities | 1.6B |
| Long-Term Debt | 376.1m |
| Other Non-Current Liabilities | 1.2B |
Earnings Waterfall
Vertex Pharmaceuticals Inc
|
Revenue
|
9.9B
USD
|
|
Cost of Revenue
|
-1.3B
USD
|
|
Gross Profit
|
8.6B
USD
|
|
Operating Expenses
|
-4.8B
USD
|
|
Operating Income
|
3.8B
USD
|
|
Other Expenses
|
-212.4m
USD
|
|
Net Income
|
3.6B
USD
|
Free Cash Flow Analysis
Vertex Pharmaceuticals Inc
VRTX Profitability Score
Profitability Due Diligence
Vertex Pharmaceuticals Inc's profitability score is 77/100. The higher the profitability score, the more profitable the company is.
Score
Vertex Pharmaceuticals Inc's profitability score is 77/100. The higher the profitability score, the more profitable the company is.
VRTX Solvency Score
Solvency Due Diligence
Vertex Pharmaceuticals Inc's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Vertex Pharmaceuticals Inc's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VRTX Price Targets Summary
Vertex Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
VRTX
is 476.77 USD
with a low forecast of 328.25 USD and a high forecast of 602.7 USD.
Ownership
VRTX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
VRTX Price
Vertex Pharmaceuticals Inc
| Average Annual Return | 14.31% |
| Standard Deviation of Annual Returns | 15.94% |
| Max Drawdown | -12% |
| Market Capitalization | 103.3B USD |
| Shares Outstanding | 260 900 000 |
| Percentage of Shares Shorted | 1.54% |
VRTX News
Last Important Events
Vertex Pharmaceuticals Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Vertex Pharmaceuticals Inc
Company Profile
Vertex Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Vertex Pharmaceuticals, Inc. is a global biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 3,900 full-time employees. The firm is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF) and it has several ongoing clinical and research programs to advance and extend treatment of CF. The firm's marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The company has a pipeline of investigational therapies in other serious diseases where it is leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. The company offers medicines for people with serious diseases with a focus on specialty markets. The firm's four medicines are being used to treat most of the people with CF in North America, Europe and Australia.
Contact
IPO
Employees
Officers
The intrinsic value of one
VRTX
stock under the Base Case scenario is
249.59
USD.
Compared to the current market price of 399.78 USD,
Vertex Pharmaceuticals Inc
is
Overvalued by 38%.
You don't have any saved screeners yet
